Grove Bank & Trust Regeneron Pharmaceuticals, Inc. Transaction History

Grove Bank & Trust

$622 Million
Q2 2024

A detailed history of Grove Bank & Trust transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Grove Bank & Trust holds 27 shares of REGN stock, worth $28,266. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 27 -0.0%

Holding current value

$28,266

Previous $25,000 12.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$775.18 - $881.7 $32,557 - $37,031	-42 Reduced 60.87%	27 $23,000
Q3 2023 Oct 30, 2023	BUY	$692.45 - $844.37 $10,386 - $12,665	15 Added 27.78%	69 $56,000
Q2 2023 Jul 27, 2023	SELL	$700.03 - $830.35 $6,300 - $7,473	-9 Reduced 14.29%	54 $38,000
Q1 2023 May 10, 2023	BUY	$680.49 - $826.97 $4,763 - $5,788	7 Added 12.5%	63 $51,000
Q4 2022 Feb 03, 2023	BUY	$705.89 - $766.39 $39,529 - $42,917	56 New	56 $40,000
Q1 2021 Apr 23, 2021	SELL	$446.73 - $548.2 $455,664 - $559,164	-1,020 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$478.3 - $607.98 $10,044 - $12,767	21 Added 2.1%	1,020 $493,000
Q3 2020 Oct 30, 2020	BUY	$544.75 - $658.21 $82,257 - $99,389	151 Added 17.81%	999 $559,000
Q2 2020 Jul 31, 2020	BUY	$493.32 - $643.92 $136,156 - $177,721	276 Added 48.25%	848 $529,000
Q1 2020 May 05, 2020	BUY	$336.18 - $494.43 $192,294 - $282,813	572 New	572 $279,000
Q4 2017 Feb 02, 2018	SELL	$358.63 - $469.95 $10,400 - $13,628	-29 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $12,510 - $14,616	29	29 $13,000

Others Institutions Holding REGN

# of Institutions

1,463

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grove Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Grove Bank & Trust with notifications on news.

Account